News Updates

More Articles Back to Article

Draft guidance by NICE backs 3 COVID-19 drugs

A new draft guidance released by the National Institute for Health and Care Excellence recommended COVID-19 treatments tocilizumab by Roche and Eli Lilly and Co.'s baricitinib in hospital settings and Pfizer's tirmatrelvir plus ritonavir in non-hospital settings. The organization withheld its recommendation for two drugs that the appraisal committee considered not cost-effective and three which did not conclusively show their effectiveness against the Omicron variant. PMLive (UK) (11/16)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!